Recurrent albendazole-induced acute hepatitis
Open accessAbstract
El albendazol es un medicamento usado para tratar infecciones por helmintos y usualmente presenta pocos o ningún efecto secundario. A pesar de que hay un incremento transitorio de enzimas hepáticas luego de su uso, existe poca evidencia en la literatura en la que se reporte lesión hepática luego de automedicación con albendazol. En este informe, el paciente se presentó con hepatitis aguda luego de automedicarse con albendazol. El paciente cuenta además con una historia de episodios similares después de haber usado el fármaco. Se evaluada la causalidad con el método de evaluación de causalidad de Roussel Uclaf del Concejo para Organizaciones Internacionales de Ciencias Médicas, cuyo resultado fue un puntaje de 10, lo que indicó una alta probabilidad de lesión hepática inducida por albendazol al cabo de realizarse una investigación rigurosa y de excluir otras posibles causas de la condición física del paciente. En conclusión, aunque es ideal agilizar el proceso para combatir a los helmintos, es necesario intensificar la necesidad de monitorizaciones de calidad para evitar reacciones adversas como la hepatitis inducida por medicamentos. Asimismo, la automedicación de cualquier medicamento debe ser siempre evitada.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Even a single dose treatment of albendazole (400 mg) could cause acute liver toxicity in adult patients as well as in children.
“Notably, however, even a single dose treatment (for empirical or seasonal use) of albendazole (400 mg) could cause acute liver toxicity in adult patients [39,314–318] as well as in children [319–322].”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [318]
Such liver toxicity may be recurrent each time after administration of albendazole.
“Such liver toxicity may be recurrent each time after administration of albendazole [317,318,320,321].”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [318]
Cites
Albendazole: a review of anthelmintic efficacy and safety in humans
HORTON, J. (2000) · Parasitology · doi:10.1017/s0031182000007290 · Cited by 386 · see citing works
Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics
Dayan, A. D. (2003) · Acta Tropica · doi:10.1016/s0001-706x(03)00031-7 · Cited by 371 · see citing works
Albendazole in hydatid disease—hepatocellular toxicity
Morris, D. L., & Smith, P. G. (1987) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(87)90259-8 · Cited by 54 · see citing works
Albendazole-induced granulomatous hepatitis: a case report
Marin Zuluaga, J. I., Marin Castro, A. E., Perez Cadavid, J. C., & Restrepo Gutierrez, J. C. (2013) · Journal of Medical Case Reports · doi:10.1186/1752-1947-7-201 · Cited by 45 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update
Chai, J.-Y., Jung, B.-K., & Hong, S.-J. (2021) · The Korean Journal of Parasitology · doi:10.3347/kjp.2021.59.3.189 · Cited by 286 · see citing works
- Authors
- Narciso-Schiavon, J. L., Delziovo, H. A., Santos, L. E. B., Shiozawa, M. B. C., & Schiavon, L. L.
- Affiliations
- Universidade Federal de Santa Catarina (BR)
- Venue
- Revista Colombiana de Gastroenterología
- Published
- 2018-12-19
- Volume
- 33
- Issue
- 4
- Pages
- 473
- ISSN
- 0120-9957 (ISSN-L)
- 2500-7440
- OpenAlex
- W2910390528
- Cited by
- 4
- References
- 4
- Citations by year
- 2026: 1 · 2022: 1 · 2021: 2
- FWCI
- 0.55
- Type
- journal article
- Language
- es
- Open access
- diamond
- doi.org
- Locations
- Revista Colombiana de Gastroenterología (publishedVersion, cc-by)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology › Drug-Induced Adverse Reactions
- Keywords
- albendazole, drug-induced hepatitis, acute hepatitis, self-medication, antiparasitic drugs, hepatotoxicity, RUCAM, adverse drug reaction monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
